Molecular biology of prostate cancer
- PMID: 7939745
Molecular biology of prostate cancer
Abstract
A number of genetic changes have been documented in prostate cancer, ranging from allelic loss to point mutations and changes in DNA methylation patterns (summarized in Fig 1). To date, the most consistent changes are those of allelic loss events, with the majority of tumors examined showing loss of alleles from at least one chromosomal arm. The short arm of chromosome 8, followed by the long arm of chromosome 16 appear to be the most frequent regions of loss, suggesting the presence of novel tumor suppressor genes. Deletions of one copy of the Rb and p53 genes are less frequent as are mutations of the p53 gene, and accumulating evidence suggests the presence of an additional tumor suppressor gene on chromosome 17p, which is frequently inactivated in prostate cancer. Alterations in the E-cadherin/alpha catenin mediated cell-cell adhesion mechanism appear to be present in almost half of all prostate cancers, and may be critical to the acquisition of metastatic potential of aggressive prostate cancers. Finally, altered DNA methylation patterns have been found in the majority of prostate cancers examined, suggesting widespread alterations in methylation-modulated gene expression. The presence of multiple changes in these tumors is consistent with the multistep nature of the transformation process. Finally, efforts to identify prostate cancer susceptibility loci are underway and will hopefully elucidate critical early events in prostatic carcinogenesis.
Similar articles
-
Molecular biology of prostate cancer progression.Cancer Surv. 1995;23:19-32. Cancer Surv. 1995. PMID: 7621457 Review.
-
Molecular genetics of prostate cancer.Cancer Surv. 1995;25:357-79. Cancer Surv. 1995. PMID: 8718527 Review.
-
Genetic alterations in prostate cancer.Cold Spring Harb Symp Quant Biol. 1994;59:653-9. doi: 10.1101/sqb.1994.059.01.075. Cold Spring Harb Symp Quant Biol. 1994. PMID: 7587126 Review.
-
Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function.Cancer Res. 1995 Nov 1;55(21):4813-7. Cancer Res. 1995. PMID: 7585512
-
Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells.Cancer Res. 1993 Aug 1;53(15):3585-90. Cancer Res. 1993. PMID: 8339265
Cited by
-
Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.Br J Cancer. 1997;75(11):1593-600. doi: 10.1038/bjc.1997.272. Br J Cancer. 1997. PMID: 9184173 Free PMC article.
-
Precursor lesions for prostate cancer.J R Soc Med. 1997 Oct;90(10):533-9. doi: 10.1177/014107689709001003. J R Soc Med. 1997. PMID: 9488009 Free PMC article. Review. No abstract available.
-
Molecular biology of prostate cancer.World J Urol. 1996;14(5):318-28. doi: 10.1007/BF00184605. World J Urol. 1996. PMID: 8912472 Review.
-
CpG island hypermethylation and repetitive DNA hypomethylation in premalignant lesion of extrahepatic cholangiocarcinoma.Virchows Arch. 2009 Oct;455(4):343-51. doi: 10.1007/s00428-009-0829-4. Epub 2009 Sep 10. Virchows Arch. 2009. PMID: 19763613
-
Three-dimensional cultures of prostatic cells: tissue models for the development of novel anti-cancer therapies.Pharm Res. 1999 Apr;16(4):486-93. doi: 10.1023/a:1011906709680. Pharm Res. 1999. PMID: 10227701 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous